Abstract：
UNASSIGNED: This study aims to conduct a cost-effectiveness analysis of pembrolizumab in combination with chemotherapy for HER2-negative advanced gastric cancer in China.
UNASSIGNED: A partitioned survival approach model was constructed to simulate the progression of HER2-negative advanced gastric cancer and evaluate the outcomes of different treatment strategies. We calculated incremental cost-effectiveness ratios (ICER) to assess the cost associated with each quality-adjusted life-year (QALY) gained. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess robustness and reliability.
UNASSIGNED: The analysis conducted in the base case demonstrated that the ICER associated with pembrolizumab was $177405.83/QALY gained in all population. In the subgroup analysis, it was found that individuals with a PD-L1 CPS ≥ 1 and those with a PD-L1 CPS ≥ 10 had ICERs of $152397.06/QALY and $109534.13/QALY, respectively. All ICER values for both the all population groups and the subgroups exceeded the WTP threshold in China. Our analysis shows the robustness of these results, as they remained consistent when input parameters were varied within a ± 25% range.
UNASSIGNED: The findings of this cost-effectiveness analysis suggest that pembrolizumab in combination with chemotherapy is not a cost-effective treatment option for HER2-negative advanced gastric cancer in China.
UNASSIGNED: A partitioned survival approach model was constructed to simulate the progression of HER2-negative advanced gastric cancer and evaluate the outcomes of different treatment strategies. We calculated incremental cost-effectiveness ratios (ICER) to assess the cost associated with each quality-adjusted life-year (QALY) gained. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess robustness and reliability.
UNASSIGNED: The analysis conducted in the base case demonstrated that the ICER associated with pembrolizumab was $177405.83/QALY gained in all population. In the subgroup analysis, it was found that individuals with a PD-L1 CPS ≥ 1 and those with a PD-L1 CPS ≥ 10 had ICERs of $152397.06/QALY and $109534.13/QALY, respectively. All ICER values for both the all population groups and the subgroups exceeded the WTP threshold in China. Our analysis shows the robustness of these results, as they remained consistent when input parameters were varied within a ± 25% range.
UNASSIGNED: The findings of this cost-effectiveness analysis suggest that pembrolizumab in combination with chemotherapy is not a cost-effective treatment option for HER2-negative advanced gastric cancer in China.
摘要：
■本研究旨在进行pembrolizumab联合化疗治疗中国HER2阴性晚期胃癌的成本效益分析。
■构建分区生存方法模型以模拟HER2阴性晚期胃癌的进展并评估不同治疗策略的结果。我们计算了增量成本效益比（ICER），以评估与获得的每个质量调整生命年（QALY）相关的成本。进行了单向敏感性分析和概率敏感性分析以评估鲁棒性和可靠性。
■在基础病例中进行的分析表明，在所有人群中，与pembrolizumab相关的ICER为$177405.83/QALY。在亚组分析中，发现PD-L1CPS≥1和PD-L1CPS≥10的个体的ICER为$152397.06/QALY和$109534.13/QALY，分别。在中国，所有人口组和亚组的所有ICER值都超过了WTP阈值。我们的分析表明了这些结果的稳健性，当输入参数在±25%范围内变化时，它们保持一致。
■这项成本效益分析的结果表明，在中国，pembrolizumab联合化疗不是HER2阴性晚期胃癌的经济有效治疗选择。
■构建分区生存方法模型以模拟HER2阴性晚期胃癌的进展并评估不同治疗策略的结果。我们计算了增量成本效益比（ICER），以评估与获得的每个质量调整生命年（QALY）相关的成本。进行了单向敏感性分析和概率敏感性分析以评估鲁棒性和可靠性。
■在基础病例中进行的分析表明，在所有人群中，与pembrolizumab相关的ICER为$177405.83/QALY。在亚组分析中，发现PD-L1CPS≥1和PD-L1CPS≥10的个体的ICER为$152397.06/QALY和$109534.13/QALY，分别。在中国，所有人口组和亚组的所有ICER值都超过了WTP阈值。我们的分析表明了这些结果的稳健性，当输入参数在±25%范围内变化时，它们保持一致。
■这项成本效益分析的结果表明，在中国，pembrolizumab联合化疗不是HER2阴性晚期胃癌的经济有效治疗选择。
